Oncology

Patients who received the chemotherapies paclitaxel and docetaxel were at an increased risk of adverse events of the eye.

More of these treatments have been approved, but supply chain issues and cost remain obstacles.

Researchers report that half of the online pharmacies are rogue operations that may operate without a license or have other serious shortcomings.

The researchers attributed low adherence to oral anti-cancer medications for blood cancer and certain other cancers to high monthly out-of-pocket among several other reasons.

New research suggests there was a 53% greater 5-year risk of cardiovascular disease in men with type 2 diabetes who received a GnRH agonist for prostate cancer compared with their counterparts who did not receive GnRH agonists.

This is the first approved therapy targeted to patients with the HER2-low breast cancer subtype. Its approval comes four months ahead of its PDUFA action date.

The specialty drug pipeline includes first- and next-in- class drugs across the oncology and immunology spaces.

Bar code medication administration has been moved beyond inpatient areas, but compliance may require improvement.

The pipeline includes next-in-class treatments for melanoma, NSCLC, breast cancer, and multiple myeloma.

Strict utilization management policies have led some patients to make decisions like skipping medication doses.

Regeneron Pharmaceuticals Inc came to an agreement to buy the drug from Sanofi for up to $1.1 billion.

Approval was based on results of the phase 3 OlympiA trial.

Multiple pharmaceutical companies are investigating the application of mRNA technology to develop vaccines that treat and prevent multiple conditions, from influenza to cancer and beyond.

A recent study investigated how the limited access to specialty care in these populations may affect the detection and diagnosis of skin cancer.

Findings from a systematic review found little difference in outcomes between biosimilar and reference product treatment options.

Cancer misinformation may be more prevalent among residents in rural vs urban areas, study finds.

Patients with chronic lymphocytic leukemia experienced functional T cell and antibody responses after receiving a vaccine for COVID-19.

Jenny Sherak, president of Specialty Physician Services at AmerisourceBergen sat down with Drug Topics® to discuss how her team provides the best customer experiences for community oncology practices across the United States.

President Biden is reviving the program he headed as vice president, with the goal of reducing the cancer mortality rate and improving the experience of patients and their loved ones.

Human papillomavirus (HPV) vaccination has significantly decreased the incidence and mortality of cervical cancer in girls and women between the ages of 15 and 24, according to a research letter in JAMA Pediatrics.

A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.

Surviving a bout of cancer early in life puts children and teenagers at risk of cancers linked to human papillomavirus (HPV). A phase 2 trial examined how effective a 3-dose series was in providing protection.

Breast cancer continues to affect women globally, with approximately 13% developing invasive disease. New treatment regimens and options are on the horizon for breast cancer therapy.

The FDA has accepted for review a biologics license application for the use of toripalimab in combination with gemcitabine and cisplatin in the frontline treatment of patients with advanced recurrent or metastatic nasopharyngeal carcinoma.

A new drug candidate demonstrated the potential to control inflammation for cancer patients in findings that were recently announced in Proceedings of the National Academy of Sciences.

In a study conducted, antidepressants slowed the growth of pancreatic and colon cancers in mice, and when combined with immunotherapy, they stopped cancer growth long-term.

IDP-126, an acne vulgaris treatment for patients ages 9 and older, met all of its endpoints in a 12-week phase 3 study.

Updated outcomes from the ongoing phase 1/2 GO40554 trial show that mosunetuzumab monotherapy demonstrated promising efficacy and a tolerable safety for elderly/unfit patients with previously untreated first-line diffuse large B-cell lymphoma.

An expert highlights the progress made with non–CAR T-based approaches in the non-Hodgkin lymphoma treatment paradigm, opportunities for sequencing available options, and ongoing efforts that are picking up momentum.

The consumer products giant voluntarily recalled 4 NEUTROGENA® and 1 AVEENO® spray sunscreen products July 14 after internal testing found low levels of benzene, a carcinogen, in some product samples.